SANIPRAZOLE

Made submissions to the FDA CDER next gen portal for Saniprazole and Saniprazole mkII

Current developments with DIOIC Biologics is in contact with NAFDAC (National Agency for Food and Drug Administration and Control) for requests to drug approvals of DRUGS with conducted trials and studies.

Research and development broke ground in June 2022, with the ideation, formulation and testing to determine the efficacy and effectiveness in treatment to a particularly detrimental health condition in and encompassing Ulcer, GERD and EOE.

Preminilary studies began on the 29th of June 2022, checking on the effects and efficasy of Saniprazole to see if there are any alleviative effects on conditions registered to the detrimental health condition in and encompassing Ulcer, GERD and EOE.

Trial studies began on the 6th of August 2022 and currently undergoing surrorogate studies [November, 2023], after ascertaining the effects and efficasy of Saniprazole, based on a consistent data of regression in condition and progression to wellness in confirmation of efficiency to the detrimental health condition in and encompassing Ulcer, GERD and EOE.

DIO Industries Corp in efficiency, efficacy and toxicity data correlation showing health advantages of Saniprazole to conditions such as Ulcer, EOE and GERD, a partnership was sort out, developed and signed with Ridho Botanicals for the manufacturing and production of Saniprazole in March, 2023 for production and Manufacturing Start Date confirmed for the 3rd of April 2023, in conjunction with Kimia Farma to treat the detrimental health condition in and encompassing Ulcer, GERD and EOE.

DIO Industries Corp is currently undergoing surrorogate studies and gearing for market entrance, in seeking a vendor, to treat the detrimental health condition in and encompassing Ulcer, GERD and EOE. In confirmation of effectiveness with BfArm [The Federal Institute for Drugs and Medical Devices (in German: Bundesinstitut für Arzneimittel und Medizinprodukte – BfArM) is the medical regulatory body in Germany.], FDA and publications to effect of Treatment.

DIO Industries Corp is currently undergoing a 7 - Day Remission surrorogate study, i.e a continous evaluation of Saniprazole in cessation usage to determine remission probability subjected to a time frame. This study commmenced on the 25th of January 2024. Conclusive result to the 7-Day study ending on Day 143, Wednesday January 31st, 2024 of the Surrogate study exhibited a zero[0 - 1] scale rating for normalcy suggesting a zero percent [0%] remission investigation and a reaction of inducive coughs with a rating of three [3] of a scaled [(0-1) of 5] with two [2] occurrences in the 7-day concurrent trial, suggesting a [28.6%] reactionary exhibition off Saniprazole on the 7-day study. Primary endpoint interpretation shows zero remissions to symptoms associated to Gastrointestinal conditions like EoE and Gerd and secondary endpoint of reactions in coughs at [28.6%].

DIO Industries Corp is currently undergoing Review with Saniprazole for approval with FDA for IND and NDA to a PHASE III; submission was made on the 15th of August 2024 for a FAST TRACK APPROVAL with all pertinent information sent in, from initial study of a monographic identification in process development in trial study to a comprehensive itemization to property phase in Phenotipic and Reactionary registration to Toxicity, Efficasy and Effieciency identity, with a Surrogate study geared to performance efficiency in alleviating Gastrointestinal Ailment to Particular EoE and Gerd!

DIO Industries Corp is currently still in discussions with multiple pharmacies and pharmaceutical companies for Licensing and Sales of Saniprazole geared to an Agreement!

DIO Industries Corp submitted applications for drug candidates Saniprazole and Saniprazole mkII for a fast track approval on the 16th of August 2024, with all pertinent information provided to. In submittal for IND and NDA approval submissions was a concurrent study on Anagelsic effects on a patient on a Gastrointestinal medication grant request which was also turned in on the 24th of September 2024. With Study/Trial conclusions to Saniprazole, Saniprazole mkII and Analgesic study of a Gastreointestinal medication also submitted officially on the 31st of October 2024. In business related association to DIOIC, an official bid was turned in for Kimia Farma, Indonesia and BioAmerica for Acquisitions.